METHOD FOR DIAGNOSING MACROPHAGE ACTIVATION SYNDROME IN A NEW CORONAVIRUS INFECTION CAUSED BY THE SARS VIRUS - COV-2 Russian patent published in 2022 - IPC G01N33/68 G01N33/573 G01N33/72 A61B5/08 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to anesthesiology and resuscitation, therapy, infectious diseases, and can be used to diagnose macrophage activation syndrome (MAS) in a new coronavirus infection caused by the SARS-CoV-2 virus. Upon admission to the hospital in the patient's venous blood serum, quantitative indicators of interleukin (IL-6), C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) are determined. Based on the data obtained, the diagnostic options for MAS are established: MAS is absent with the following indicators: the level of IL-6 in the blood serum is 0.1-5 pg/ml, the level of CRP is 0.2-15 mg/l, the level of LDH is 200-450 U/l , ferritin level 20-300 mcg/l, there are no signs of acute respiratory failure (ARF); moderate CAM with the following indicators: IL-6 level in the range of 5.1-49 pg / ml, CRP level - 16-60 mg/l, LDH level - 451-550 U/l, ferritin level - 301-800 mcg/l , signs of ARF I degree; pronounced CAM with the following indicators: IL-6 level in the range of 50-300 pg/ml, CRP level - more than 61 mg/l, LDH level - 551-2000 U/l, ferritin level - 801-3500 mcg/l, signs of ARF II degree.

EFFECT: method enables early diagnosis of MAS and ARF in patients with a new coronavirus infection caused by the SARS-CoV-2 virus, and determination of the severity of MAS due to the fact that, upon admission to a hospital, the patient's blood serum levels of IL-6, CRP are determined , ferritin and LDH, as well as assess the presence or absence of ARF.

1 cl, 5 ex